B-CELL NON HODGKIN LYMPHOMA

This study is testing a new version of CAR T-cell therapy for adults with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or not responded to other treatments. The therapy uses a patient's own modified immune cells, which are specially processed to …

This early-stage study aims to find safe and effective doses of loncastuximab tesirine (an approved lymphoma drug) when combined with other anti-cancer drugs. It is for adults whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments. The main goal is t…

This early-stage study is testing the safety and initial effectiveness of a new cell therapy for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to standard treatments. Doctors will give patients specially modified immune cells, called CAR NK cells, wh…

This study tests whether a personalized support plan helps older adults with blood cancers recover physical function faster after CAR-T cell therapy. Researchers will compare two groups: one receiving standard care and one receiving extra support including physical therapy, nutri…

This study is testing whether adding a new immunotherapy drug, epcoritamab, to a standard chemotherapy regimen (called EPOCH-R) is safe and more effective for treating aggressive B-cell lymphomas. The trial will enroll about 18 adults who have not yet received treatment for their…

This early-stage trial is testing a new experimental drug called IKS03 in adults with advanced B-cell non-Hodgkin lymphomas that have returned or stopped responding to standard treatments. The study aims to find the safest and most effective dose by first testing increasing amoun…

This study is testing a two-part treatment for patients with B-cell lymphoma that has come back or hasn't responded to standard treatments. First, patients receive a high-dose chemotherapy and their own stem cell transplant. Then, three days later, they receive an infusion of spe…

This international trial is testing three promising new types of medicines for children and young adults (up to age 25) whose B-cell non-Hodgkin lymphoma has come back or hasn't responded to standard treatments. The goal is to find safer, more effective options, as current treatm…

This early-stage study is testing a two-part treatment to prevent aggressive B-cell lymphoma from coming back after a stem cell transplant. Doctors take a patient's own immune cells, modify them to target cancer, and infuse them back. They then give a vaccine designed to boost th…

This study is testing the safety and effectiveness of a new two-drug combination for people with advanced solid tumors, including pancreatic cancer, that have spread or stopped responding to standard treatments. The trial aims to find the best dose and see if the drugs can help c…

This early-stage trial is testing a new treatment for patients whose blood cancers have returned or not responded to standard therapies. The treatment uses a modified virus that is designed to selectively infect and kill cancer cells while sparing healthy ones. Researchers are st…

This study aims to monitor the long-term safety and effectiveness of Miltenyi's CAR T cell therapies in patients who were treated at least a year ago. It will follow 40 patients with various cancers, including lymphoma, leukemia, and melanoma, to check for any late side effects a…

This study is testing whether a combination of two drugs, pembrolizumab and tazemetostat, can help prevent aggressive B-cell lymphoma from coming back after a patient has received a stem cell transplant or CAR T-cell therapy. The drugs are given as a 12-month maintenance treatmen…

This study is testing an experimental drug called surovatamig for adults whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior treatments. The main goals are to see if the drug can shrink the cancer and how safe it is for patients. Researcher…

This is an early-stage study testing a new type of personalized cell therapy called MC10029 for adults with B-cell blood cancers that have come back or stopped responding to standard treatments. Researchers will first find the safest dose and then see if the therapy can shrink tu…

This early-stage study is testing a new antibody drug called AZD0486 in people with B-cell non-Hodgkin lymphoma that has returned or stopped responding to previous treatments. Researchers will give increasing doses to about 317 participants to find the safest amount and check for…

This early-stage study is testing a new drug called AZD0486, both alone and combined with other cancer treatments, for people with advanced B-cell blood cancers that have returned or stopped responding to prior therapies. It aims to find a safe dose and see if the drug can shrink…

This study is testing a new drug called AZD4512 for adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior treatments. The main goals are to find a safe dose and see if the drug helps control the cancer. It will involve about 91 par…

This early-stage study is testing a new drug called SAR448501/DR-0201 in adults whose B-cell non-Hodgkin lymphoma has returned or hasn't responded to at least two prior standard treatments. The main goals are to find a safe dose and see if the drug shows any signs of fighting the…

This is an early-stage study testing a new type of CAR-T cell therapy called CT1190B. It aims to see if this treatment is safe and effective for adults with B-cell non-Hodgkin lymphoma that has come back or hasn't responded to standard treatments. The study will also look at how …